|Videos|June 8, 2023
Selecting Between Doublet and Triplet Regimens for Patients With Transplant-Ineligible NDMM
April Logue, APRN-CNP, shares her perspective on selecting between doublet and triplet regimens for patients with transplant-ineligible newly-diagnosed multiple myeloma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
3
What Were the Key Hematologic Oncology Takeaways from SOHO 2026?
4
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
5